Ben-Baruch G, Menczer J, Feldman B, Rizel S, Brenner H
Department of Obstetrics and Gynecology, Sheba Medical Center Tel Hashomer, Sackler School of Medicine, Tel Aviv University, Israel.
Eur J Gynaecol Oncol. 1994;15(4):272-6.
In a previously published study we compared the outcome probability within 3 years after diagnosis in two groups of advanced ovarian carcinoma patients in complete clinical remission with minimal or no residual disease at second look laparotomy, performed after completion of cisplatin based combination chemotherapy. One group (n = 18) received after reexploration, abdominopelvic irradiation (RT group), the other diagnosed during a later period (n = 19), received after reexploration three courses of introperitoneal cisplatin chemotherapy with systemic thiosulfate protection (IP) group). In the present study the outcome of the same patients is compared after they have all been followed for at least 5 years or till death. A clear trend towards a more favorable, through statistically not significant, 5 year survival was observed (68%), in the IP group, vs 39% in the RT group (p = 0.07). In patients with a negative second-look laparotomy, the respective 5 year survival rates were 92% and 60% (p = 0.08). While the duration of the progression-free interval was similar in both treatment groups the survival after diagnosis of recurrence was significantly better in the IP group (41% vs 0%, p = 0.03).
在一项先前发表的研究中,我们比较了两组晚期卵巢癌患者在诊断后3年内的预后概率。这两组患者在以顺铂为基础的联合化疗完成后进行二次剖腹探查时,处于完全临床缓解状态,残留病灶极少或无残留病灶。一组(n = 18)在再次探查后接受腹盆腔照射(放疗组),另一组在较晚时期确诊(n = 19),在再次探查后接受三个疗程的腹腔内顺铂化疗并给予全身硫代硫酸盐保护(腹腔化疗组)。在本研究中,对相同患者在全部随访至少5年或直至死亡后的预后进行了比较。腹腔化疗组观察到有一个更有利的5年生存率趋势(68%),尽管在统计学上不显著,而放疗组为39%(p = 0.07)。在二次剖腹探查结果为阴性的患者中,各自的5年生存率分别为92%和60%(p = 0.08)。虽然两个治疗组的无进展生存期相似,但腹腔化疗组在复发诊断后的生存率明显更好(41%对0%,p = 0.03)。